Thanks to Reviewers

Therapeutic Advances in Chronic Disease · Published 2025-01-01 · DOI 10.1177/20406223251316507

Authors being retrieved — see the publisher record. https://doi.org/10.1177/20406223251316507

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis · Therapeutic Advances in Chronic Disease · 2024 · Same journal
Hepatitis and periodontal health: an emerging oral-liver axis · Therapeutic Advances in Chronic Disease · 2025 · Same journal
Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study · Therapeutic Advances in Chronic Disease · 2025 · Same journal
Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication · Therapeutic Advances in Chronic Disease · 2025 · Same journal
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis · Therapeutic Advances in Chronic Disease · 2024 · Same journal
Cyclosporin A as an adjunct may enhance the therapeutic effect of interferon alpha-2a in patients with refractory Behcet’s uveitis: a retrospective cohort study · Therapeutic Advances in Chronic Disease · 2024 · Same journal
Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea · Therapeutic Advances in Chronic Disease · 2024 · Same journal
The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira · Therapeutic Advances in Chronic Disease · 2024 · Same journal
Willingness to start insulin therapy among insulin-naïve persons with type 2 diabetes mellitus at Gulu Regional Referral Hospital, Gulu City, Uganda · Therapeutic Advances in Chronic Disease · 2024 · Same journal
Aortic arch calcification increases major adverse cardiac event risk, modifiable by echocardiographic left ventricular hypertrophy, in end-stage kidney disease patients · Therapeutic Advances in Chronic Disease · 2024 · Same journal